Regenxbio(RGNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RGNX Regenxbio

Trading 03-11 12:46:31 EDT

9.32

-0.58

-5.86%

High9.80	Low9.15	Vol370.80K
Open9.80	D1 Closing9.90	Amplitude6.57%
Mkt Cap481.03M	Tradable Cap400.75M	Total Shares51.61M
T/O3.47M	T/O Rate0.86%	Tradable Shares43.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RGNX","market":"US","secType":"STK","nameCN":"Regenxbio","latestPrice":9.32,"timestamp":1773247588520,"preClose":9.9,"halted":0,"volume":370795,"delay":0,"changeRate":-0.05858585858585859,"floatShares":42998600,"shares":51612984,"eps":-3.759292,"marketStatus":"Trading","change":-0.58,"latestTime":"03-11 12:46:31 EDT","open":9.8,"high":9.8,"low":9.15,"amount":3465917.0863024998,"amplitude":0.065657,"askPrice":9.33,"askSize":1,"bidPrice":9.29,"bidSize":4,"shortable":3,"etf":0,"ttmEps":-3.759292,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1773259200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1442462400000,"exchange":"NASDAQ","adjPreClose":9.9,"preHourTrading":{"tag":"盘前","latestPrice":9.79,"preClose":9.9,"latestTime":"09:29 EDT","volume":2401,"amount":23961.612646999998,"timestamp":1773235799999,"change":-0.11,"changeRate":-0.011111,"amplitude":0.031313},"postHourTrading":{"tag":"盘后","latestPrice":10.1,"preClose":9.9,"latestTime":"19:36 EDT","volume":5973,"amount":59176.15,"timestamp":1773185817684,"change":0.2,"changeRate":0.020202,"amplitude":0.020202},"volumeRatio":0.541585,"impliedVol":1.2918,"impliedVolPercentile":0.8406},"requestUrl":"/m/hq/s/RGNX/tweets","defaultTab":"tweets","newsList":[{"id":"2618921027","title":"Regenxbio Reports 'Positive' Interim Data in Duchenne Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2618921027","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618921027?lang=en_us&edition=fundamental","pubTime":"2026-03-12 00:37","pubTimestamp":1773247037,"startTime":"0","endTime":"0","summary":"Regenxbio  said Wednesday new interim results of its gene therapy RGX-202 study in Duchenne muscular dystrophy showed evidence of \"positively\" changing disease trajectory.The company said favorable safety profile continued with no serious adverse events or adverse events of special interest observed in the phase I/II study.The firm also said it expects pivotal topline data in Q2 and plans to seek a pre-Biologics License Application meeting with the US Food and Drug Administration in mid-2026.Shares were down more than 6% in midday trading.Price: 9.22, Change: -0.68, Percent Change: -6.87","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RGNX","BK4505","BK4139","BK4563"],"gpt_icon":0},{"id":"2618929037","title":"Regenxbio's Duchenne gene therapy shows improved muscle function in trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2618929037","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618929037?lang=en_us&edition=fundamental","pubTime":"2026-03-11 23:59","pubTimestamp":1773244776,"startTime":"0","endTime":"0","summary":"Regenxbio's Duchenne gene therapy shows improved muscle function in trialMarch 11  - Regenxbio RGNX.O said on Wednesday that an interim data from a early-to-mid stage study of its experimental gene therapy in patients with Duchenne muscular dystrophy showed continued improvement in muscle function and a clean safety profile.  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL4N3ZZ1OH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4505","RGNX","BK4139"],"gpt_icon":0},{"id":"2618092142","title":"Regenxbio reports interim data from Phase I/II AFFINITY DUCHENNE trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2618092142","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618092142?lang=en_us&edition=fundamental","pubTime":"2026-03-11 23:56","pubTimestamp":1773244570,"startTime":"0","endTime":"0","summary":"REGENXBIO (RGNX) announced newinterim data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202, a potential gene therapy for Duchenne muscular d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenxbio-reports-interim-data-from-phase-i-ii-affinity-duchenne-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenxbio-reports-interim-data-from-phase-i-ii-affinity-duchenne-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4563","BK4139","RGNX","BK4505"],"gpt_icon":0},{"id":"2618292389","title":"Regenxbio reports Phase I/II AFFINITY DUCHENNE interim RGX-202 data with NSAA up 5 points at 1 year","url":"https://stock-news.laohu8.com/highlight/detail?id=2618292389","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618292389?lang=en_us&edition=fundamental","pubTime":"2026-03-11 23:45","pubTimestamp":1773243936,"startTime":"0","endTime":"0","summary":"Regenxbio reported interim data from the Phase I/II AFFINITY DUCHENNE trial evaluating RGX-202 for Duchenne muscular dystrophy, and the results were presented by Carolina Tesi-Rocha at the MDA Clinical and Scientific Conference. In seven participants treated at 2x10^14 GC/kg, NSAA improved by 5 points versus the cTAP model at 1 year. Cardiac MRI measures in these seven participants showed left ventricular ejection fraction of 62% at baseline and 62% at 12 months. In biomarker analyses , an additional patient had microdystrophin expression of 51% at Week 12, and the pivotal phase primary endpoint is the proportion of participants with expression above 10% at Week 12. Regenxbio said pivotal topline data are expected in early Q2 2026, with a pre-BLA meeting request planned for mid-2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL5jr5ct:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","RGNX","BK4505","BK4139"],"gpt_icon":0},{"id":"2618992928","title":"Regenxbio Inc - to Request Pre-Bla Meeting With FDA in Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618992928","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618992928?lang=en_us&edition=fundamental","pubTime":"2026-03-11 23:45","pubTimestamp":1773243900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA7JTMYM:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGNX","BK4139","BK4563","BK4505"],"gpt_icon":0},{"id":"2618929285","title":"Regenxbio Inc - Pivotal Topline Data Expected in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618929285","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618929285?lang=en_us&edition=fundamental","pubTime":"2026-03-11 23:45","pubTimestamp":1773243900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA7JTMYM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4563","RGNX","BK4139"],"gpt_icon":0},{"id":"2618929281","title":"Regenxbio Reports New Positive Interim Data From Phase I/Ii Affinity Duchenne® Trial of Rgx-202","url":"https://stock-news.laohu8.com/highlight/detail?id=2618929281","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618929281?lang=en_us&edition=fundamental","pubTime":"2026-03-11 23:45","pubTimestamp":1773243900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA7JTMYM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4505","BK4563","RGNX"],"gpt_icon":0},{"id":"2618292839","title":"Regenxbio Inc - No Serious Adverse Events Observed in Phase I/Ii Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2618292839","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618292839?lang=en_us&edition=fundamental","pubTime":"2026-03-11 23:45","pubTimestamp":1773243900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA7JTMYM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4505","RGNX","BK4563"],"gpt_icon":0},{"id":"2618589940","title":"Regenxbio CMO Stephen Pakola named defendant in RGX-111 securities class action after 18% share drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2618589940","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618589940?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:03","pubTimestamp":1773234233,"startTime":"0","endTime":"0","summary":"Regenxbio and its Chief Medical Officer Stephen Pakola are named as defendants in a securities class action alleging the company’s public statements about the safety of RGX-111 concealed material risks from investors. The complaint alleges Pakola repeatedly said RGX-111 was “well-tolerated” and that there were “no drug-related serious adverse events” in disclosures from February 2022 to November 2023. After information emerged on January 28, 2026, Regenxbio shares fell USD 2.4, or 18%, to USD 11.01. The suit also asserts a controlling-person claim against Pakola under Section 20 of the Securities Exchange Act.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL5ZKJHz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4563","RGNX","BK4139"],"gpt_icon":0},{"id":"2618391679","title":"REGENXBIO Up Over 17%, on Track for Largest Percent Increase Since November 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2618391679","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618391679?lang=en_us&edition=fundamental","pubTime":"2026-03-10 02:45","pubTimestamp":1773081900,"startTime":"0","endTime":"0","summary":"REGENXBIO, Inc.  is currently at $10.16, up $1.51 or 17.46%. --Would be highest close since Feb. 9, 2026, when it closed at $10.31. --On pace for largest percent increase since Nov. 7, 2024, when it rose 18.66%. --Down 87.63% from its all-time closing high of $82.15 on July 10, 2018. --Up 69.05% from 52 weeks ago , when it closed at $6.01. --Down 36.42% from its 52-week closing high of $15.98 on Jan. 22, 2026. --Up 91.34% from its 52-week closing low of $5.31 on April 8, 2025. --Traded as high as $10.76; highest intraday level since Feb. 6, 2026, when it hit $10.95. --Up 24.39% at today's intraday high; largest intraday percent increase since March 5, 2024, when it rose as much as 34.83%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"REGENXBIO Up Over 17%, on Track for Largest Percent Increase Since November 2024 -- Data Talk","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","RGNX","BK4563"],"gpt_icon":0},{"id":"2618794620","title":"LIVE MARKETS-Prasad's exit a win for biotechs, but don't celebrate yet","url":"https://stock-news.laohu8.com/highlight/detail?id=2618794620","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618794620?lang=en_us&edition=fundamental","pubTime":"2026-03-09 23:49","pubTimestamp":1773071361,"startTime":"0","endTime":"0","summary":"LIVE MARKETS-Prasad's exit a win for biotechs, but don't celebrate yetMain US stock indexes negative, but well off earlier lows; Nasdaq now off ~0.2%Financials weakest S&P 500 sector; Tech leads gaine","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL1N3ZX0RX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314106906.USD","BK4585","LU0106831901.USD","LU1506573853.SGD","LU0980610538.SGD","LU0052756011.USD","BK4207","LU0162691827.USD","LU2360032135.SGD","LU1267930227.SGD","RGNX","LU0128525689.USD","LU0648001328.SGD","LU0072461881.USD","LU2236285917.USD","BK4505","LU0320765646.SGD","LU2456880835.USD","LU1201861249.SGD","LU2462157665.USD","LU2125154935.USD","LU1244550577.SGD","BK4559","IE00BSNM7G36.USD","LU1244550494.USD","LU1162221912.USD","LU0130517989.USD","BK4139","LU0310800965.SGD","LU1668664300.SGD","LU0477156953.USD","LU0098860793.USD","BK4534","BK4566","LU2125154778.USD","LU1791807156.HKD","LU0130102774.USD","BK4588","LU0170899867.USD","LU1244550221.USD","LU1366192091.USD","LU2417539215.USD","BK4563","BK4504"],"gpt_icon":0},{"id":"2618620753","title":"BUZZ-U.S. STOCKS ON THE MOVE-Biotechs, Agilent, Dow","url":"https://stock-news.laohu8.com/highlight/detail?id=2618620753","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618620753?lang=en_us&edition=fundamental","pubTime":"2026-03-09 23:46","pubTimestamp":1773071217,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Biotechs, Agilent, DowWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:/","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL6N3ZX16R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAL","HIMY","LYV","SATS","CAT","CDE","NEMG","XENE","AALG","HIMZ","IRON","JPMO","DTIL","DUK","COHX","NEM","HMYY","RGNX","AGH","PLD","VRT","CAPR","FCEL","XOMO","LITX","JEF","SATG","COP","DOW","NWMX","SLB","LUV","XOMZ","RLMD","PFE","NBP","DAL","HL","BAC","ITT","RAPP","DE","VRTL","XOMX","UAL"],"gpt_icon":1},{"id":"2618629228","title":"BUZZ-Biotechs gain as FDA vaccines chief's exit seen as easing regulatory pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2618629228","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618629228?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:19","pubTimestamp":1773062349,"startTime":"0","endTime":"0","summary":"BUZZ-Biotechs gain as FDA vaccines chief's exit seen as easing regulatory pathway** Shares of some biotech companies rise premarket as head of U.S. health regulator's vaccines and biologics unit Vinay Prasad set to leave the agency in April ** \"We believe his departure will lead to a much more favorable regulatory environment for certain companies such as Regenxbio RGNX.O\" - Clear Street** Shares of UniQure UQ1.F, Disc Medicine IRON.O, Capricor Therapeutics CAPR.O and Regenxbio climb between 1.5% and 35% in trading before the bell      ** \"Overall, we believe Dr. Prasad's departure is likely a tailwind for the biotech sector, particularly in cases of regulatory flexibility for companies developing novel therapies for rare diseases, but we would caution against celebrating before a replacement is disclosed\" - William Blair ** Truist analysts said while they expect his departure to be viewed positively by industry stakeholders, the overall outlook remains far from clear until it becomes ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL4N3ZX1B2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRON","CAPR","BK4139","BK4505","BK4563","LU0053671581.USD","RGNX"],"gpt_icon":0},{"id":"2618462921","title":"This biotech's stock is soaring after a 'polarizing' FDA official is stepping down","url":"https://stock-news.laohu8.com/highlight/detail?id=2618462921","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618462921?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:18","pubTimestamp":1773062280,"startTime":"0","endTime":"0","summary":"Shares of UniQure, which is developing a gene therapy for Huntington's disease, are rallying. Vinay Prasad, an official for the Food and Drug Administration, is reportedly stepping down.UniQure's stock  was up 38% in premarket trading on Monday. Late Friday, the FDA told the Wall Street Journal that Vinay Prasad plans to leave the agency next month. He is the director of the FDA's Center for Biologics Evaluation and Research, which oversees vaccines and rare-disease drugs.Prasad had reportedly been involved in the decision to request a new trial for uniQure's experimental gene therapy for Huntington's disease. UniQure's stock plunged on that request, falling 33% in a single day, and the action led to a broader discussion about the expertise of current FDA leadership and how rare-disease-focused biotechs have struggled to advance therapies under those leaders.\"Prasad was a polarizing figure as exemplified by his involvement in rare-disease drug regulatory reversals, an initial refusal  ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4534","BK4588","LU0109394709.USD","RGNX","BK4548","BK4563","MRNX","BK4532","BK4585","LU0889565916.HKD","BK4568","BK4581","MRNY","BK4551","BK4139","BK4533","QURE","BK4501","LU0320765992.SGD","XBI","BK4505"],"gpt_icon":1},{"id":"2618647160","title":"REGENXBIO Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647160","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618647160?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:39","pubTimestamp":1773052740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RGNX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 06:39 ET (10:39 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","BK4563","RGNX"],"gpt_icon":0},{"id":"2618647890","title":"Regenxbio price target lowered to $30 from $32 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647890","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618647890?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:15","pubTimestamp":1773051330,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Regenxbio (RGNX) to $30 from $32 and keeps a Buy rating on the shares following the Q4 report. P...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenxbio-price-target-lowered-to-30-from-32-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenxbio-price-target-lowered-to-30-from-32-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RGNX"],"gpt_icon":0},{"id":"2617652837","title":"RegenXbio Faces FDA Clinical Holds: Heightened Development Risk, Potential Delays, and Investor Uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=2617652837","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617652837?lang=en_us&edition=fundamental","pubTime":"2026-03-07 14:01","pubTimestamp":1772863294,"startTime":"0","endTime":"0","summary":"RegenXBio Inc. (RGNX) has disclosed a new risk, in the Innovation / R&D category. RegenXbio Inc. faces heightened development and regulatory risk b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regenxbio-faces-fda-clinical-holds-heightened-development-risk-potential-delays-and-investor-uncertainty?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regenxbio-faces-fda-clinical-holds-heightened-development-risk-potential-delays-and-investor-uncertainty?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","RGNX","BK4139","BK4563"],"gpt_icon":0},{"id":"2617663132","title":"REGENXBIO Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2617663132","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617663132?lang=en_us&edition=fundamental","pubTime":"2026-03-07 00:04","pubTimestamp":1772813040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RGNX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2026 11:04 ET (16:04 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","RGNX","BK4563"],"gpt_icon":0},{"id":"2617574720","title":"Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Kura Oncology (KURA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617574720","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617574720?lang=en_us&edition=fundamental","pubTime":"2026-03-06 06:40","pubTimestamp":1772750407,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on RegenXBio (RGNX – Research Report) and Kura Oncology...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-regenxbio-rgnx-and-kura-oncology-kura-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-regenxbio-rgnx-and-kura-oncology-kura-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4585","LABU","BK4563","BK4505","BK4137","BK4581","LU0029874061.USD","RGNX","BK4588","XBI","HCSG","KURA","XLV","BK4139"],"gpt_icon":0},{"id":"2617573493","title":"Regenxbio price target lowered to $17 from $18 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2617573493","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617573493?lang=en_us&edition=fundamental","pubTime":"2026-03-06 04:15","pubTimestamp":1772741732,"startTime":"0","endTime":"0","summary":"Morgan Stanley lowered the firm’s price target on Regenxbio (RGNX) to $17 from $18 and keeps an Overweight rating on the shares after the company r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenxbio-price-target-lowered-to-17-from-18-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenxbio-price-target-lowered-to-17-from-18-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RGNX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regenxbio.com","stockEarnings":[{"period":"1week","weight":0.1392},{"period":"1month","weight":-0.0416},{"period":"3month","weight":-0.242},{"period":"6month","weight":0.0432},{"period":"1year","weight":0.6473},{"period":"ytd","weight":-0.3125}],"compareEarnings":[{"period":"1week","weight":-0.0046},{"period":"1month","weight":-0.0195},{"period":"3month","weight":-0.0151},{"period":"6month","weight":0.0297},{"period":"1year","weight":0.208},{"period":"ytd","weight":-0.007}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":-0.091067},{"month":2,"riseRate":0.272727,"avgChangeRate":0.000501},{"month":3,"riseRate":0.636364,"avgChangeRate":0.022489},{"month":4,"riseRate":0.6,"avgChangeRate":0.035795},{"month":5,"riseRate":0.3,"avgChangeRate":-0.022478},{"month":6,"riseRate":0.6,"avgChangeRate":0.047674},{"month":7,"riseRate":0.4,"avgChangeRate":-0.001741},{"month":8,"riseRate":0.4,"avgChangeRate":0.017624},{"month":9,"riseRate":0.6,"avgChangeRate":0.07131},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.060741},{"month":11,"riseRate":0.727273,"avgChangeRate":0.164969},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.05132}],"exchange":"NASDAQ","name":"Regenxbio","nameEN":"Regenxbio"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regenxbio(RGNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Regenxbio(RGNX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Regenxbio,RGNX,Regenxbio股票,Regenxbio股票老虎,Regenxbio股票老虎国际,Regenxbio行情,Regenxbio股票行情,Regenxbio股价,Regenxbio股市,Regenxbio股票价格,Regenxbio股票交易,Regenxbio股票购买,Regenxbio股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regenxbio(RGNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Regenxbio(RGNX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction